BIO-UV Group (ALTUV) Fair Value & Analysis
Industrials · FR · Market cap €19.1M
Fair value as of: Jun 24, 2026
Analysis
BIO-UV Group (ALTUV) currently trades at €1.35, while our model-based Fair Value estimate is €1.29 — implying the stock looks roughly 4.4% overvalued today. We read business quality at 95/100 (high quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
BIO-UV Group S.A. designs, manufactures, and markets water treatment and disinfectant systems using ultraviolet, salt electrolysis, ozone, and advanced oxidation for individuals and professionals in France, rest of Europe, Asia, the Middle East, the Americas, and internationally. It operates through Products, Solutions, and After-Sales divisions. The company offers disinfection equipment and systems under the triogen, AKERON, 1001 Electrodes, and BIOSEA brands; spare parts; and commissioning services. It also provides maintenance services comprising inspection and diagnosis; cleaning and replacement of parts; calibration and adjustments; updates and upgrades; and training and technical support services. The company's products are used in residential and commercial pools, aquariums, aquaculture, industrial water, municipal and domestic water, wastewater and reuse, and ballast water applications. It exports its products. BIO-UV Group S.A. was founded in 2000 and is headquartered in Lu…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is BIO-UV Group (ALTUV) undervalued?
What is the fair value of ALTUV?
What is the quality score of ALTUV?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.